Angela M Urmanski is a pharmacist who is specialized in Oncology in Milwaukee, Wisconsin. Patients can reach her at 9200 W Wisconsin Ave, Milwaukee or contact her on 414-805-3145. Active license number of Angela M Urmanski is 1243340 for Oncology in Wisconsin. Angela M Urmanski is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Angela M Urmanski speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Angela M Urmanski
Specialization:
Oncology
Credentials:
PHARMD, BCOP
Gender:
Female
Location:
9200 W Wisconsin Ave, Milwaukee, Wisconsin, 53226-3522
Phone:
414-805-3145
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Angela M Urmanski are as mentioned below.
NPI Number:
1134494107
NPI Enumeration Date:
09 Mar, 2012
NPI Last Update On:
09 Mar, 2012
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Angela M Urmanski are as mentioned below.
Specialization
License Number
State
Status
Oncology
1243340
Wisconsin
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
9200 W Wisconsin Ave, Milwaukee, Wisconsin
Zip:
53226-3522
Phone Number:
--
Fax Number:
--
Patients can reach Angela M Urmanski at 9200 W Wisconsin Ave, Milwaukee, Wisconsin or can call on phone at 414-805-3145.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.